文献速递前列腺癌

前列腺癌根治术后淋巴结复发挽救性淋巴结清扫的长期结局:不如既往认为的那么好

Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
PubMed 文献 · Eur Urol · 2020-07-02

该多中心回顾性研究纳入189例根治性前列腺切除术后仅淋巴结复发并接受挽救性淋巴结清扫(sLND)的患者,中位随访87个月。10年癌症特异性生存和无癌特异性死亡生存分别为66%和64%,无临床复发和无生化复发生存分别为31%和11%。sLND后PSA反应和6个月内接受ADT与更低的PCa死亡风险相关。

要点

  • sLND后10年无临床复发和无生化复发生存分别仅31%和11%。
  • sLND后10年癌症特异性生存为66%,多数死亡归因于前列腺癌。
  • sLND后PSA反应及6个月内ADT与更低的PCa死亡风险相关。

核心结论

  • sLND治疗的PET检测淋巴结复发前列腺癌患者中约三分之一长期死亡,前列腺癌是主要死因。
  • 仅少数患者从sLND单独治疗中获得持久长期获益,数据不支持对仅淋巴结复发患者单独使用转移灶定向治疗。

研究设计与样本

  • 多中心回顾性系列研究,纳入2002至2011年间11家三级转诊中心189例根治性前列腺切除术后PSA升高且仅淋巴结复发并接受sLND的患者。
  • 淋巴结复发通过11C-胆碱或68Ga-PSMA配体PET/CT记录。
  • 主要结局为癌症特异性死亡(CSM),次要结局包括总死亡、临床复发(CR)、生化复发(BCR)和ADT无进展生存。

主要发现

  • 长期随访中110例发生CR、163例发生BCR,10年无CR生存31%、无BCR生存11%。
  • sLND后145例接受ADT,中位至ADT时间41个月。
  • 存活者中位随访87个月(IQR 51-104),48例死亡,其中45例死于前列腺癌。
  • 10年无癌症特异性死亡和无全因死亡概率分别为66%和64%。
  • 多变量分析中,sLND后PSA反应(HR 0.45;p=0.001)和sLND后6个月内接受ADT(HR 0.51;p=0.010)与更低的PCa死亡风险相关。

临床怎么用

  • 应将仅淋巴结复发的前列腺癌患者视为已有全身播散高风险,sLND应作为多模式治疗的一部分而非唯一治疗策略。
  • sLND后PSA反应和早期(6个月内)ADT使用与更低PCa死亡风险相关,可考虑在sLND后整合ADT。

局限性

  • 回顾性多中心设计,可能存在选择偏倚。
  • 随访期间ADT使用和其他后续治疗可能影响结局。
  • 敏感性分析仅限盆腔阳性PET/CT、排除PET/CT时已用ADT及PSA高于75百分位的患者,结果相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term outcomes of patients treated with salvage lymph node dissection (sLND) for nodal recurrence of prostate cancer (PCa) remain unknown. OBJECTIVE: To investigate long-term oncological outcomes after sLND in a large multi-institutional series. DESIGN, SETTING, AND PARTICIPANTS: The study included 189 patients who experienced prostate-specific antigen (PSA) rise and nodal-only recurrence after radical prostatectomy (RP) and underwent sLND at 11 tertiary referral centers between 2002 and 2011. Lymph node recurrence was documented by positron emission tomography/computed tomography (PET/CT) scan using either 11C-choline or 68Ga prostate-specific membrane antigen ligand. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome of the study was cancer-specific mortality (CSM). The secondary outcomes were overall mortality, clinical recurrence (CR), biochemical recurrence (BCR), and androgen deprivation therapy (ADT)-free survival after sLND. The probability of freedom from each outcome was calculated using Kaplan-Meier analyses. Cox regression analysis was used to predict the risk of prostate CSM after accounting for several parameters, including the use of additional treatments after sLND. RESULTS AND LIMITATIONS: At long term, 110 and 163 patients experienced CR and BCR, respectively, with CR-free and BCR-free survival at 10 yr of 31% and 11%, respectively. After sLND, a total of 145 patients received ADT, with a median time to ADT of 41 mo. At a median (interquartile range) follow-up for survivors of 87 (51, 104) mo, 48 patients died. Of them, 45 died from PCa. The probabilities of freedom from cancer-specific and all-cause death at 10 yr were 66% and 64%, respectively. Similar results were obtained in sensitivity analyses in patients with pelvic-only positive PET/CT scan, as well as after excluding men on ADT at PET/CT scan and patients with PSA level at sLND higher than the 75th percentile. At multivariable analyses, patients who had PSA response after sLND (hazard ratio [HR]: 0.45; p = 0.001), and those receiving ADT within 6 mo from sLND (HR: 0.51; p = 0.010) had lower risk of death from PCa. CONCLUSIONS: A third of men treated with sLND for PET-detected nodal recurrence of PCa died at long term, with PCa being the main cause of death. Salvage LND alone was associated with durable long-term outcomes in a minority of men who significantly benefited from additional treatments after surgery. Taken together, all these data argue against the use of metastasis-directed therapy alone for patients with node-only recurrent PCa. These men should instead be considered at high risk of systemic dissemination already at the time of sLND. PATIENT SUMMARY: We assessed long-term outcomes of patients treated with salvage lymph node dissection (sLND) for node-recurrent prostate cancer (PCa). In contrast with prior evidence, we found that the majority of these men recurred after sLND and eventually died from PCa. A significant survival benefit associated with the administration of androgen deprivation therapy after sLND suggests that sLND should be considered part of a multimodal approach rather than an exclusive treatment strategy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Bravi CA, Fossati N, Gandaglia G, et al. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. Eur Urol. 2020. PMID: 32624288. doi:10.1016/j.eururo.2020.06.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。